A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis.

[Guest guest]

http://www.jcge.com/pt/re/jclngastro/abstract.00004836-200810000-00012.htm;jsessionid=LXQbNkL4gPFJm1g4298bJQpxLsfzMTGFhRM0cLB2w8X16xTvY18J!1455807198!181195628!8091!-1

A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis.

LIVER, PANCREAS AND BILIARY TRACT Journal of Clinical Gastroenterology. 42(9):1032-1039, October 2008.Gluck, MD; Cantone, Nico R. BS; Brandabur, J. MD; , J. MD; Bredfeldt, E. MD; Kozarek, A. MD

Abstract: Goals: The current study presents 1 tertiary endoscopy center's 20-year experience using endoscopic therapy to treat patients with symptomatic primary sclerosing cholangitis (PSC). Background: Endoscopic therapy for patients with PSC and dominant strictures has been used for more than 20 years, but there is concern that instrumenting a sclerotic biliary tree induces risks that outweigh anticipated benefits. Study: In this retrospective chart review, 117 patients with PSC were identified using ICD-9 codes. Patients had a mean age of 47 years (range: 15 to 86 y). Mean duration of follow-up was 8 years (range: 2 to 20 y). Of the 117 identified patients, 106 underwent endoscopic retrograde cholangiopancreatography on one or more occasions (for a total of 317 endoscopic retrograde cholangiopancreatographies), and a subset of 84 patients received endoscopic therapy for treatment of dominant strictures and/or deteriorating clinical status. Actual survival for endoscopically treated patients was compared with predicted survival using the Mayo Clinic natural history model for PSC. Results: Our chart review revealed 23 recognized complications among the 317 procedures performed (7.3%), and no procedure-related deaths. Observed patient survival at years 3 and 4 was significantly higher than that predicted by the Mayo Clinic natural history model for PSC (P=0.021). Conclusions: Patients with PSC who have a deteriorating clinical course benefited from endoscopic therapy to provide drainage of bile ducts, removal of stones, and/or temporary relief from obstructions, with acceptable procedure-related complications and higher than expected 3-year and 4-year survival. © 2008 Lippincott & Wilkins, Inc.